Trial Profile
Prospective, 2-year, open-label study of the safety, efficacy, quality of life and persistence of fingolimod in relapsing remitting multiple sclerosis patients in Argentina
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 May 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms REAL
- 21 Apr 2016 Results of an interim analysis (n=181) presented at the 68th Annual Meeting of the American Academy of Neurology
- 08 Jun 2015 New trial record